289 related articles for article (PubMed ID: 32376602)
1. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
2. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
4. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
[TBL] [Abstract][Full Text] [Related]
5. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
6. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
7. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
8. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
9. The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
Maity G; Haque I; Ghosh A; Dhar G; Gupta V; Sarkar S; Azeem I; McGregor D; Choudhary A; Campbell DR; Kambhampati S; Banerjee SK; Banerjee S
J Biol Chem; 2018 Mar; 293(12):4334-4349. PubMed ID: 29414775
[TBL] [Abstract][Full Text] [Related]
10. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
11. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
13. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
14. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
[TBL] [Abstract][Full Text] [Related]
18. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
19. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer.
Wang Q; Li J; Wu W; Shen R; Jiang H; Qian Y; Tang Y; Bai T; Wu S; Wei L; Zang Y; Zhang J; Wang L
Oncotarget; 2016 Mar; 7(10):11208-22. PubMed ID: 26848620
[TBL] [Abstract][Full Text] [Related]
20. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer.
Chen HD; Ye Z; Hu HF; Fan GX; Hu YH; Li Z; Li BR; Ji SR; Zhou CJ; Xu XW; Yu XJ; Qin Y
Acta Pharmacol Sin; 2024 Apr; 45(4):844-856. PubMed ID: 38057506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
